Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

On February 28, 2023, Cabaletta Bio (Nasdaq: CABA) announced that CEO Steven Nichtberger, M.D., will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference. This event is set for March 7, 2023, at 2:10 p.m. ET in Boston, MA. A live webcast will be accessible on the company’s website, with replays available for 30 days post-event.

Cabaletta Bio focuses on developing innovative T cell therapies aimed at treating autoimmune diseases. Their CABA™ platform includes the CARTA and CAART strategies, with promising candidates like CABA-201 and DSG3-CAART, which may offer curative solutions for various conditions.

PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m. ET in Boston, MA.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing CD19-CAR T, as the lead product candidate, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform may offer potentially curative therapies for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters are located in Philadelphia, PA.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

FAQ

When is Steven Nichtberger participating in the Cowen 43rd Annual Health Care Conference?

Steven Nichtberger will participate in the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 2:10 p.m. ET.

Where can I watch the live webcast of the Cowen Conference presentation by Cabaletta Bio?

The live webcast of the presentation will be available on Cabaletta Bio's website in the News and Events section.

What therapies is Cabaletta Bio developing?

Cabaletta Bio is focused on developing engineered T cell therapies aimed at treating autoimmune diseases, including CABA-201 and DSG3-CAART.

What is the CABA™ platform of Cabaletta Bio?

The CABA™ platform encompasses two strategies: CARTA, which includes CABA-201, and CAART, which features clinical-stage candidates like DSG3-CAART.

How long will the replay of the fireside chat be available?

Replays of the fireside chat will be available on the Cabaletta Bio website for 30 days following the event.